Promising Results Shown For Kidney Cancer Drug, Temple University Study

Published: Feb 04, 2010

EurekAlert! -- The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology.

Back to news